Myeloma Registry Platform (MYRIAM)

Last updated: January 26, 2026
Sponsor: iOMEDICO AG
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Myeloma

Platelet Disorders

Bone Neoplasm

Treatment

Routine care as per site standard.

Clinical Study ID

NCT03308474
iOM-060331
  • Ages > 18
  • All Genders

Study Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • MM requiring systemic (first-, second- or third-line) treatment (closed forfirst-line / second-line recruitment)

  • Age ≥ 18 years

  • Written informed consent

  • Patients participating in the PRO satellite: signing of informed consent andcompletion of baseline questionnaire before, but not more than eight weeksbefore the start of respective systemic treatment

  • Patients not participating in the PRO satellite: signing of informed consentnot later than four weeks after start of respective treatment, and not morethan eight weeks before the start of respective systemic treatment

  • Sufficient German language skills for participation in the PRO satellite

Exclusion

Exclusion Criteria:

  • No systemic therapy for myeloma

  • Patients already enrolled in studies that prohibit any participation in otherstudies

Study Design

Total Participants: 2200
Treatment Group(s): 1
Primary Treatment: Routine care as per site standard.
Phase:
Study Start date:
September 25, 2017
Estimated Completion Date:
December 31, 2028

Study Description

MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.

Connect with a study center

  • Multiple sites all over germany

    Multiple Locations,
    Germany

    Site Not Available

  • Multiple sites all over germany

    Multiple Sites,
    Germany

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.